Northwestern Journal of Technology and Intellectual Property
Volume 14 | Issue 1

Article 4

2016

Do Not Pass Go, Do Not Stop for Summary
Judgment: The U.S. District Court for the District
of Delaware’s Seemingly Disjunctive Yet Efficient
Procedures in Hatch-Waxman Litigation
Katherine Rhoades
k-rhoades2016@nlaw.northwestern.edu

Recommended Citation
Katherine Rhoades, Do Not Pass Go, Do Not Stop for Summary Judgment: The U.S. District Court for the District of Delaware’s Seemingly
Disjunctive Yet Efficient Procedures in Hatch-Waxman Litigation, 14 Nw. J. Tech. & Intell. Prop. 81 (2016).
https://scholarlycommons.law.northwestern.edu/njtip/vol14/iss1/4

This Comment is brought to you for free and open access by Northwestern Pritzker School of Law Scholarly Commons. It has been accepted for
inclusion in Northwestern Journal of Technology and Intellectual Property by an authorized editor of Northwestern Pritzker School of Law Scholarly
Commons.

Copyright 2016 by Northwestern University Pritzker School of Law
Northwestern Journal of Technology and Intellectual Property

Volume 14, Number 1 (2016)

Do Not Pass Go, Do Not Stop for Summary
Judgment: The U.S. District Court for the District
of Delaware’s Seemingly Disjunctive Yet Efficient
Procedures in Hatch-Waxman Litigation
By Katherine Rhoades *
ABSTRACT
With the multi-billion dollar generic pharmaceutical industry growing annually,
litigation under the Hatch-Waxman Act—the legislation that expedited the Food & Drug
Administration’s (“FDA”) approval process for generic drugs—can have substantial
economic implications on American consumers. Under the Hatch-Waxman Act, a generic
drug company can challenge a brand-name pharmaceutical company’s pioneer drug
patent(s) in an Abbreviated New Drug Application (“ANDA”) by filing a Paragraph IV
certification with the FDA, and the patentee can—and usually does—sue for infringement.
The court may find the pioneer drug patent(s) invalid or not infringed by the generic drug,
which results in savings to American consumers when the affordable generic drug is
eventually brought to market. The United States District Court for the District of
Delaware’s four Article III judges hear the majority of cases arising under the HatchWaxman Act. However, unlike other patent-heavy dockets, the District of Delaware does
not have uniform local patent rules and very rarely entertains motions for summary
judgment in Hatch-Waxman litigation. This article evaluated the District of Delaware’s
procedures in handling Hatch-Waxman cases and presents an empirical study of the
district’s summary judgment practice in these cases. The empirical study shows that the
District of Delaware’s practice is efficient and predictable and not contrary to the purpose
behind the Hatch-Waxman Act: to bring more low-cost generic drugs to consumers.
Because the district has a bench experienced in patent litigation, the District of Delaware
does not need to adopt local patent rules and should continue its current practice of rarely
hearing summary judgment motions in ANDA cases.
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INTRODUCTION
¶1

¶2

¶3

The United States pharmaceutical industry is a multi-billion dollar industry that
continues to grow. Generic drug companies make up a large part of the pharmaceutical
market, accounting for roughly seventy-one percent of the prescription drugs purchased
annually. 1 Many Americans rely on these low-cost alternatives to brand-name drugs, but
this booming industry did not always exist. The prior lengthy and expensive Food & Drug
Administration (“FDA”) approval regime for pharmaceutical drugs left little incentive for
generic drug manufacturers to seek FDA approval. This resulted in few low-cost
alternatives for Americans unhappy with costly brand-name drug prices.
Congress sought to increase the availability of low-cost generic drugs to consumers.
In September 1984, Congress created a streamlined approval process for generic drugs by
passing the Drug Price Competition and Patent Term Restoration Act of 1984, which
launched a new era in the generic drug industry. 2 This landmark legislation, commonly
known as the Hatch-Waxman Act, allows a generic drug manufacturer (“generic”) to file
an Abbreviated New Drug Application (“ANDA”) with the FDA, which significantly
expedited the process to get the FDA approval necessary for bringing many generic drugs
to the market. Congress sought to strike a balance between generics and innovators with
this new legislation. Along with the expedited approval process for generics, the HatchWaxman Act also provided additional incentives to innovators such as a patent term
extension and restrictions on the generic drugs eligible for the ANDA process. 3 For
example, the Hatch-Waxman Act does not allow generics to place generic equivalents of
patented drugs on the market, and owners of valid pharmaceutical patents can seek recourse
in federal court under the Hatch-Waxman Act. 4
The United States District Court for the District of Delaware and the United States
District Court for the District of New Jersey are overwhelmingly the favored jurisdictions
of brand-name pharmaceutical companies seeking to enjoin generics from placing their
allegedly infringing generic drugs on the market under the Hatch-Waxman Act. 5 This is
due in part to the high number of drug companies headquartered or incorporated in
Delaware or New Jersey. The local rules and local practice governing ANDA cases in
these two districts vary significantly. Hatch-Waxman litigation in the District of Delaware
can be described as “courtroom-specific”; that is, the local rules and procedures vary
noticeably among its four Article III judges. 6 In comparison, the District of New Jersey
1

Somnath Pal, Shifts in the Generic-Drug Market: Trends and Causes, U.S. PHARMACIST (June 21,
2013), http://www.uspharmacist.com/content/s/253/c/41309/ [https://perma.cc/QZY3-YEUP].
2
See Drug Price Competition and Patent Term Restoration Act of 1984 § 101, 21 U.S.C. § 355(j)
(1984).
3
See id. § 201, 35 U.S.C. § 156 (1984); id. § 101.
4
See id. § 202, 35 U.S.C. § 271(e).
5
Kevin E. Noonan, Lex Machina Looks at ANDA Cases, PATENT DOCS (Nov. 5, 2014),
http://www.patentdocs.org/2014/11/lex-machina-looks-at-anda-cases.html [https://perma.cc/RPM7-X5JR];
Brian C. Howard, 2014 Patent Litigation Year in Review, LEX MACHINA 1, 13 (Mar. 26, 2015),
http://pages.lexmachina.com/rs/lexmachina/images/2014 Patent Litigation Report.pdf
[https://perma.cc/T2ZR-D7Y7] (“ANDA litigation is heavily concentrated in the Districts of New Jersey
and Delaware.”). The most litigation occurs in the District of Delaware, followed by the District of New
Jersey. Noonan, supra note 5.
6
See Judges’ Info, U.S. DISTRICT. CT. DISTRICT. DEL., http://www.ded.uscourts.gov/judges-info
[https://perma.cc/6SXT-W2JQ].
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has adopted uniform local patent rules with Hatch-Waxman-specific provisions that govern
all ANDA cases in the district, regardless of which of its twenty-five Article III judges
presides over the case. 7 Additionally, Delaware’s judges seldom allow ANDA litigants to
bring motions for summary judgment.
The Hatch-Waxman Act seeks to accelerate the process of bringing low-cost generic
drugs to consumers. This article explores some of the District of Delaware’s practices and
procedures in handling ANDA cases to see whether those practices frustrate the purpose
behind the Hatch-Waxman Act by delaying the release of these low-cost drugs to the
market. Part I presents the important provisions of the Hatch-Waxman Act that give rise
to ANDA litigation, as well as the policies behind the Act. Part II explores the local rules
and local practice in the District of Delaware and compares it with the District of New
Jersey. This article focuses specifically on the District of Delaware but references the
District of New Jersey’s local rules and procedures to contrast with Delaware. Part III
presents an empirical study of summary judgment motion practice in ANDA cases in those
two districts. Part IV concludes that while the District of Delaware’s local rules and
procedures may seem disjunctive and inefficient at first glance, the district does not need
uniform local patent rules because the judges are extremely experienced and efficient in
handling patent cases, and of most relevance, in ANDA cases. However, Part IV further
explains that the District of Delaware could improve its handling of ANDA cases by
requiring early disclosure of the ANDA in litigation.
I. BACKGROUND OF THE HATCH-WAXMAN ACT

¶5

The Hatch-Waxman Act amended the Federal Food, Drug, and Cosmetic Act, and
“effectively created the modern generic pharmaceutical industry.” 8 By enacting the HatchWaxman Act, Congress provided the FDA with a new complex regulatory scheme to
govern the approval of generic drugs. 9 The approval process allows generics to get their
lower-cost alternatives on the market more quickly than under the previous FDA regime.

7
See D.N.J. L. CIV. R. App. T. In 2011, New Jersey was selected to participate in the congressionally
enacted Patent Pilot Program, see Pilot Program in Certain District Courts, Pub. L. No. 111-349 § 1, 124
Stat. 3674 (2011), and has adopted procedures for the allocation of patent cases in its district, see D.N.J. L.
CIV. R. 40.1(f); D.N.J. L. PAT. R. 1.5. Delaware was not selected to participate in the pilot program. See
Ron Vogel, The Patent Pilot Program: Reassignment Rates and the Effect of Local Patent Rules, NYIPLA
13, 13 (Oct./Nov. 2013), http://www.fr.com/files/Uploads/Documents/Vogel.NYIPLABulletin.Pilot-PatentProgram-Reassignment-Rates-and-Effects-of-Local-Rules.OctNov2013.pdf [https://perma.cc/BY2J-B45B].
The Patent Pilot Program allows judges to transfer patent cases on their docket to a judge in the district who
has opted to participate in the program. See id. “Delaware was the only patent-intense district not included
in the Program.” Id. Since Delaware has only four Article III judges, its non-participation in the program
is not unusual.
8
Matthew Avery, Continuing Abuse of the Hatch-Waxman Act by Pharmaceutical Patent Holders and
the Failure of the 2003 Amendments, 60 HASTINGS L.J. 171, 175 (2008).
9
Colleen Kelly, The Balance Between Innovation and Competition: The Hatch-Waxman Act, the 2003
Amendments, and Beyond, 66 FOOD & DRUG L.J. 417, 417 (2011).
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A. ANDA Approval Process
¶6

¶7

Under the Hatch-Waxman Act, a generic seeking FDA approval of its drug may file
an ANDA with the FDA 10 rather than a New Drug Application (“NDA”). 11 In comparison,
before a research-based pharmaceutical company can market its pioneer drug, it must
submit an NDA containing extensive pre-clinical and clinical data establishing the drug’s
safety and efficacy. 12 Before the Hatch-Waxman Act, a generic seeking FDA approval
had to submit an NDA. This meant that if an NDA submitted by the pioneer
pharmaceutical company of the same drug had already been approved, the FDA still
required the generic to file a lengthy NDA containing clinical data of the generic version
of the approved drug even though the FDA had already concluded that the drug was safe
and effective by approving the first NDA. 13 This regulatory system slowed the
development of marketable generic equivalents. 14 Under the current system, rather than
requiring the generic to submit full clinicals on safety and efficacy of the generic drug, the
Hatch-Waxman Act instead requires that a generic submit an ANDA containing scientific
data showing that the drug is the “bioequivalent” 15 of a drug approved in an NDA. 16
The Hatch-Waxman regulatory scheme ensures that generic drugs meet FDA quality
standards, while simplifying the generic drug approval process. This encourages the
development of generic drugs, thereby accelerating consumer access to these affordable
drugs. 17 An ANDA applicant can rely entirely on the pioneer pharmaceutical company’s
lengthy and costly clinical data provided in the approved NDA and has no obligation to
provide the FDA with its own proof of safety and efficacy as long as the generic can prove
bioequivalency. 18
10

21 U.S.C. § 355(j) (2015).
Id. § 355(a).
12
See Avery, supra note 8, at 174–75 (discussing the extensive testing and analysis pharmaceutical
companies perform in order to prove the drug’s safety and efficacy in an NDA).
13
Id.
14
See id. In fact, “just before the Hatch-Waxman Act was passed, the FDA estimated there were
approximately 150 brand-name drugs on the market with expired patents but no generic equivalents.” Id.
15
Under the Hatch-Waxman Act:
A drug shall be considered to be bioequivalent to a listed drug if—
(i) the rate and extent of absorption of the drug do not show a significant difference from the rate and
extent of absorption of the listed drug when administered at the same molar dose of the therapeutic
ingredient under similar experimental conditions in either a single dose or multiple doses; or
(ii) the extent of absorption of the drug does not show a significant difference from the extent of
absorption of the listed drug when administered at the same molar dose of the therapeutic ingredient
under similar experimental conditions in either a single dose or multiple doses and the difference from
the listed drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is
not essential to the attainment of effective body drug concentrations on chronic use, and is considered
medically insignificant for the drug.
21 U.S.C. § 355(j)(8)(B).
16
Kelly, supra note 9, at 417. When filing an ANDA with the FDA, a generic need only “demonstrate
that its generic drug has the same active ingredient, the same basic pharmacokinetics, and is bioequivalent
to the pioneer drug.” Avery, supra note 8, at 176; see 21 U.S.C. § 355(j)(2)(A)(ii)–(iv). This does not
suggest that the generic need only prove bioequivalency in its ANDA. A generic must submit a variety of
information to the FDA in its ANDA, including chemistry manufacturing and controls. See 21 U.S.C. §
355(j)(b)(2)(A)(vi). Therefore, while the amount of information submitted in an ANDA is substantially
less than an NDA, there is still some meat to an ANDA.
17
Avery, supra note 8, at 176.
18
Id.; see Janssen Pharmaceutica, N.V. v. Apotex, Inc., 540 F.3d 1353, 1356 (Fed. Cir. 2008) (“Generic
11
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This eliminates duplicative research and clinical trial costs previously required of
generics. 19
¶9
Even if a generic proves that its generic drug is the “bioequivalent” of a drug
approved in an NDA, there are limits to the FDA’s approval power. The FDA cannot
approve an ANDA for a generic drug that will infringe a valid patent. 20 When filing an
ANDA, the generic must certify that the drug it seeks to market is (I) not patented, (II) the
patent has expired, (III) the generic drug will not go on the market until the patent expires,
or (IV) the “patent is invalid or will not be infringed by the manufacture, use, or sale of the
[generic] drug . . . .” 21 These are referred to as Paragraph I, II, III, and IV certifications
respectively. By filing a Paragraph IV certification, a generic seeks to market an equivalent
of a patented drug before the patent has expired when it believes the patent is invalid, not
infringed, or unenforceable. 22 But the Hatch-Waxman Act prohibits the FDA from
approving an ANDA “until all patent protection and market exclusivity periods have
expired.” 23
¶10
Once the FDA approves an ANDA containing a Paragraph IV certification, the
generic receives 180-day marketing exclusivity for its approved generic drug. 24 The
exclusivity period seeks to encourage and reward the first Paragraph IV challenger “for
undertaking the costs and risks of patent litigation” in filing an ANDA challenging the
validity of the patent. 25 Thus, a successful Paragraph IV challenger is given six months to
market its generic drug without any generic competition. 26
B. Purpose and Policy of the Hatch-Waxman Act
¶11

The Hatch-Waxman Act was designed as a compromise between competing policy
objectives. 27 One the one hand, Congress sought to increase the availability of low cost,

drug companies are not required to conduct their own independent clinical trials to prove safety and
efficacy, but can instead rely on the research of the pioneer pharmaceutical companies.”).
19
See Avery, supra note 8, at 176. And by not requiring generics to undertake duplicative clinical trials,
the Act allows for safe, previously patented generic drug equivalents to reach consumers, while saving
Americans billions of dollars. See Kelly, supra note 9, at 426.
20
See 21 U.S.C. § 355(j)(2)(A)(vii)(I)–(IV).
21
Id.
22
Michael R. Herman, The Stay Dilemma: Examining Brand and Generic Incentives for Delaying the
Resolution of Pharmaceutical Patent Litigation, 111 COLUM. L. REV. 1788, 1795 (2011).
23
Kelly, supra note 9, at 418. By including this requirement, Congress sought to encourage generics to
challenge stale patents on the market, while also giving valid patents the utmost protection to encourage
innovation. See Janssen Pharmaceutica, 540 F.3d at 1355–56.
24
21 U.S.C. § 355(j)(5)(B)(iv).
25
Avery, supra note 8, at 178 (quoting Representative Henry Waxman, Speech at the Generic
Pharmaceutical Association’s First Annual Policy Conference: Securing the Future of Affordable Medicine
(Sept. 20, 2005)).
26
Avery, supra note 8, at 178. This period may be cut short. For example, the “180-day exclusivity can
begin to run—with a court decision—even before an applicant has received approval for its ANDA. In that
case, some, or all of the 180-day period, could expire without the ANDA applicant marketing its generic
drug.” FTC Study: Generic Drug Entry Prior to Patent Expiration: Before the Senate Committee on the
Judiciary (2003) (statement of Daniel E. Troy, Chief Counsel, FDA),
http://www.fda.gov/NewsEvents/Testimony/ucm161034.htm [https://perma.cc/2QSW-ZCKQ].
27
See aaiPharma Inc. v. Thompson, 296 F.3d 227, 230 (4th Cir. 2002) (citations and internal quotation
marks and omitted) (discussing how the Hatch-Waxman Act was an “effort to strike a balancing between
two conflicting policy objectives”).
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generic drugs for American consumers. 28 On the other hand, in doing so, Congress did not
want to discourage research-based pharmaceutical companies from investing in the
research and development of new drugs. 29 Legislators wanted to continue to incentivize
pharmaceutical companies to research and invent new drugs to treat medical conditions. 30
To achieve these objectives, Congress created the ANDA approval process for noninfringing generic drugs to increase competition among generics and research-based
pharmaceutical drug companies, as well as competition between generics, thereby lowering
costs to consumers. 31
Additionally, to provide incentives for research-based
pharmaceutical companies to continue invest in research and development, the HatchWaxman Act included “patent term extensions of up to five years to compensate for
marketing delays during the regulatory review period prior to the first permitted
commercial marketing of a new drug.” 32
C. Paragraph IV Certifications
¶12

Litigation frequently arises under the Hatch-Waxman Act. Hatch-Waxman litigation
arises when a generic files an ANDA with the FDA containing a “[P]aragraph IV
certification challenging a brand drug manufacturer’s patent(s)”. 33 Filing an ANDA with
a Paragraph IV certification is itself an act of patent infringement. 34 Therefore, the HatchWaxman Act requires all Paragraph IV ANDA filers to provide notice to the challenged
patent holder (“patentee”), which should “include a detailed statement of the factual and
legal basis” of why the applicant believes “that the patent is invalid or will not be
infringed.” 35 Upon receipt of the notice, the patent holder can bring an infringement action
against the ANDA applicant within forty-five days. 36 However, if the patent holder fails
to file a suit within that time, “the approval [of the ANDA] shall be made effective
immediately” upon the FDA’s completion of substantive review of the ANDA. 37

28

See H.R. REP. NO. 98–857, pt. 1, at 14 (1984) (“The purpose of Title I of the bill is to make available
more low cost generic drugs by establishing a generic drug approval procedure for pioneer drugs first
approved after 1962.”); Avery, supra note 8, at 172 (noting that such a balance of rights is necessary to
prevent pharmaceutical pioneers from reaping “monopoly profits indefinitely”).
29
Kelly, supra note 9, at 417; see Avery, supra note 8, at 171 (noting that “[t]he pharmaceutical industry
is one of the few industries that requires patent protection to ensure the profitability of its innovative
products” due to the enormous costs that companies must sink into research and development).
30
Kelly, supra note 9, at 417.
31
Id.
32
Rebecca S. Eisenberg, The Role of the FDA in Innovation Policy, 13 MICH. TELECOMM. & TECH. L.
REV. 345, 357–58 (2007); see Drug Price Competition and Patent Term Restoration Act of 1984 § 201, 35
U.S.C. § 156 (1984).
33
2014 Patent Litigation Study, PRICEWATERHOUSECOOPERS 1, 20 (2014),
http://www.pwc.com/en_US/us/forensic-services/publications/assets/2014-patent-litigation-study.pdf
[https://perma.cc/PP35-S5ZF].
34
See 35 U.S.C. § 271(e)(2)(A) (2015) (“It shall be an act of infringement to submit . . . [an ANDA] for
a drug claimed in a patent or the use of which is claimed in a patent . . . .”).
35
21 U.S.C. § 355(j)(2)(B)(iv)(II).
36
Id. § 355(j)(5)(B)(iii); see also 35 U.S.C. § 271(e)(5) (allowing a generic to bring a declaratory
judgment action against the patentee if the patentee fails to bring an infringement action within the fortyfive day period).
37
21 U.S.C. § 355(j)(5)(B)(iii). While the statute uses the “immediately” language, it is a bit
misleading. If no suit is filed within forty-five days, that does not mean that the ANDA will be approved
on day forty-six. It may take years for the FDA to complete its substantive review of the ANDA.
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If the patent holder does assert its patent against the ANDA filer within the forty-five
day time period, it automatically triggers a thirty-month stay. 38 During the thirty-month
stay, “the FDA is barred from approving the ANDA” but may tentatively approve the
application, which “become[s] effective immediately upon expiration of the stay.” 39 The
stay is intended to protect patent holders with valid drug patents, 40 but if the patent expires
or if a district court finds the patent invalid or not infringed by the ANDA, the FDA can
immediately approve the ANDA before expiration of the thirty-month stay. 41
¶14
The litigation between patentees and ANDA filers are bench trials that rarely award
damages. 42 Damages are rare in these suits because the alleged infringer has not put the
drug on the market yet, and thus, usually has not made any infringing sales prior to the
suit. 43 Instead, patentees seek injunctive relief from the court to prevent a generic from
putting their drug on the market. 44 Because patentees risk losing patent protection on their
highly profitable brand-name drugs, the potential economic implications of ANDA
litigation are significant.
II. LOCAL RULES AND SUMMARY JUDGMENT PRACTICE IN THE DISTRICT
OF DELAWARE
¶15

At first glance, in comparing the two most favored ANDA litigation districts, the
District of Delaware’s rules and procedures in handling ANDA cases appear disjunctive
and inefficient compared to the District of New Jersey’s rules and practice. ANDA
litigation has grown substantially in the past decade, and Delaware and New Jersey are the
most active districts for ANDA litigation by far. 45 These two districts combined have
handed down almost half of all ANDA court decisions since 1995, 46 which is not surprising
since these districts are home to many pharmaceutical companies. However, the local court
rules governing ANDA cases in the District of Delaware and the District of New Jersey
are significantly different. Also, the local procedures in ANDA cases, specifically
summary judgment practice, differ considerably between these two districts. While this
article focuses specifically on ANDA litigation in the District of Delaware, New Jersey’s
local rules and practice are referred to for comparison. It is worth comparing the districts’
procedures in handling ANDA cases to evaluate whether the District of Delaware’s rules
and practice are efficient in furthering the objectives of the Hatch-Waxman Act.

38

See id.
Avery, supra note 8, at 177; see 21 U.S.C. § 355(j)(5)(B)(iv)(II)(dd).
40
Avery, supra note 8, at 177.
41
See 21 U.S.C. § 355(j)(5)(B)(iii)(I)–(II).
42
See Brian D. Coggio et al., The Right to a Jury Trial in Actions Under the Hatch-Waxman Act, 79 J.
PAT. & TRADEMARK OFF. SOC’Y 765, 767 (1997).
43
See id.
44
See id.; see 35 U.S.C. § 271(e)(4).
45
Noonan, supra note 5; see Howard, supra note 5, at 13; 2013 Patent Litigation Study,
PRICEWATERHOUSECOOPERS 1, 28 (2013), http://www.pwc.com/en_US/us/forensicservices/publications/assets/2013-patent-litigation-study.pdf [https://perma.cc/7N4E-SA88]. The “most
ANDA litigation occurs in the District of Delaware (678 cases),” followed by “the District of New Jersey
(481 cases) . . . .” Noonan, supra note 5.
46
See 2013 Patent Litigation Study, supra note 45, at 28; see also Noonan, supra note 5. Since 1995,
there have been 137 ANDA court decisions, and sixty-two of those decisions were handed down by judges
in Delaware or New Jersey. 2013 Patent Litigation Study, supra note 45, at 28
39

88

Vol. 14:1]

Katherine Rhoades

A. The Local Rules: Delaware vs. New Jersey
¶16

Over the last decade, patent rules have become an integral part of patent litigation. 47
At least twenty-four U.S. district courts have formally adopted local patent rules to govern
patent litigation. 48 The District of New Jersey is one of those many districts. 49 The District
of New Jersey has also amended its local patent rules to include unique disclosure
provisions exclusive to patent cases arising under the Hatch-Waxman Act. 50 The District
of Delaware has not followed suit. Delaware has adopted neither rules to govern HatchWaxman cases nor any local patent rules. 51 New Jersey’s bench has twenty-five Article
III judges 52 while the District of Delaware has four. 53 The purpose of local patent rules is
to increase predictability and efficiency by promoting uniformity among the district, 54 so
uniform local patent rules may be more important in districts with more district court
judges, such as the District of New Jersey. However, like several other districts, the District
of Delaware’s individual judges do have standing orders similar to local patent rules. 55
B. The District of Delaware’s Local Rules

¶17

The District of Delaware’s local rules differ significantly from the District of New
Jersey’s local patent rules and Hatch-Waxman provisions. Most apparent is the fact that
Delaware has not adopted local patent rules, let alone Hatch-Waxman provisions. 56 In fact,
among its Local Civil Rules, Delaware has only one rule specifically directed at patent
cases. 57

47

See Travis Jensen, Basics, LOCAL PATENT RULES, http://www.localpatentrules.com/basics/ (last
visited Mar. 5, 2016) [https://perma.cc/J799-E4YB]. The Northern District of California was the first to
adopt local patent rules in 2001. Arthur Gollwitzer III, Local Patent Rules—Certainty and Efficiency or a
Crazy Quilt of Substantive Law?, 13 ENGAGE: J. FEDERALIST SOC’Y PRAC. GROUPS 94, 94 (2012).
48
Gollwitzer, supra note 47, at 94; see generally D.N.J. L. PAT. R.; E.D. TEX. P.R.; N.D. ILL. LPR.
District courts have authority to adopt local patent rules under Federal Rule of Civil Procedure 83.
Gollwitzer, supra note 47, at 95; see FED. R. CIV. P. 83.
49
See generally D.N.J. L. PAT. R. These rules govern all civil actions “which allege infringement of a
patent in a complaint, counterclaim, cross-claim or third party claim, or which seek a declaratory judgment
that a patent is not infringed, is invalid or is unenforceable.” D.N.J. L. PAT. R. 1.2.
50
See D.N.J. L. PAT. R. 3.6 (“Disclosure Requirements for Patent Cases Arising Under 21 U.S.C. § 355
(commonly referred to as “the Hatch-Waxman Act”)).
51
See generally D. DEL. LR.
52
At the time this article was written, the District of New Jersey had fourteen active Article III judges,
eight Article III judges with senior status, and three judicial vacancies. United States District Court for the
District of New Jersey, BALLOTPEDIA,
https://ballotpedia.org/United_States_District_Court_for_the_District_of_New_Jersey (last visited Feb. 26,
2016) [https://perma.cc/LYC3-JK77]; see Our Judges, U.S. DISTRICT CT. DISTRICT N.J.,
http://www.njd.uscourts.gov/our-judges (last visited Feb. 26, 2016) [https://perma.cc/Y7HY-TRGV].
53
Judges’ Info, U.S. DISTRICT CT. DISTRICT DEL., http://www.ded.uscourts.gov/judges-info (last visited
Mar. 9, 2016) [https://perma.cc/VV2R-WVE7].
54
See Gollwitzer, supra note 47, at 94. With more judges, there is more potential for variation between
judges.
55
See Jensen, supra note 47; see e.g., Standing Orders, U.S. DISTRICT CT. DISTRICT DEL.,
http://www.ded.uscourts.gov/court-info/local-rules-and-orders/general-orders (last visited Mar. 9, 2016)
[https://perma.cc/7TA4-9VVN].
56
See generally, D. DEL. LR.
57
See D. DEL. LR 3.2 (“In all patent cases, copies of the patents at issue shall be attached and filed with
the complaint.”).
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1. Delaware’s ANDA Procedures and Its Judges’ Idiosyncrasies
¶18

Since the District of Delaware has not adopted local patent rules, the procedures
governing ANDA cases in Delaware are “courtroom specific.” The District of Delaware
has one division, and its bench comprises only four Article III judges—Chief Judge
Leonard P. Stark, Judge Sue L. Robinson, Judge Gregory M. Sleet, and Judge Richard G.
Andrews. 58 While Delaware has not adopted local patent rules, its individual judges have
standing orders and guidelines that operate in effect like local patent rules. 59 However,
unlike uniform local patent rules, the standing orders and guidelines are specific to the
individual judge. 60 For example, each judge has his or her own model scheduling order
for patent cases that sets out his or her general default procedures. 61 But the pertinent
procedures for each judge vary considerably, and thus, the procedures governing ANDA
cases in Delaware depend on to whose courtroom the parties are assigned.
¶19
In June 2014, Chief Judge Leonard P. Stark implemented new patent procedures for
handling patent cases in his courtroom. 62 Those revised procedures include provisions
governing almost all aspects of litigation, including: discovery, scheduling and case
management, motions, invalidity and infringement contentions, Markman hearings, 63
summary judgment, Daubert motions, 64 pretrial orders, and trial. 65 However, these patent
procedures govern only “all non-ANDA patent cases” assigned to Chief Judge Stark. 66 The
Chief Judge also has two different scheduling orders for patent cases: (1) Patent Scheduling

58
See Comparison of the Most Popular Patent Venues, LAW360 (Dec. 10, 2009),
http://www.cooley.com/files/Law360.Patent Venue Article. Mitchell.Tilly.pdf [https://perma.cc/9FUAFVUT]; see also Judges Info, supra note 53.
59
See Standing Orders, supra note 55. Each judge also has procedures and guidelines to govern patent
cases in their courtroom that they post on their individual pages on the district’s website. See also Judges
Info, supra note 53.
60
See Judges Info, supra note 53.
61
See e.g., Revised Patent Form Scheduling Order (ANDA), U.S. DISTRICT CT. DISTRICT DEL. (July 1,
2014), http://www.ded.uscourts.gov/sites/default/files/Chambers/LPS/PatentProcs/LPS-PatentSchedOrderANDA.pdf [https://perma.cc/22VY-FAVX] [hereinafter Chief J. Stark’s ANDA Patent Scheduling Order];
Patent Case Scheduling Order, U.S. DISTRICT CT. DISTRICT DEL. (Feb. 5, 2015),
http://www.ded.uscourts.gov/sites/default/files/Chambers/SLR/Forms/Sched-Order-Patent2-05-15.pdf
[https://perma.cc/228C-TU3N] [hereinafter J. Robinson’s Patent Scheduling Order].
62
See Honorable Leonard P. Stark, Revised Procedures for Managing Patent Cases, U.S. DISTRICT CT.
DISTRICT DEL. 1, 1 (June 18, 2014),
http://www.ded.uscourts.gov/sites/default/files/Chambers/LPS/PatentProcs/LPS-PatentProcedures.pdf
[https://perma.cc/5WQW-XCJG] [hereinafter Chief J. Stark’s Patent Procedures].
63
In Markman v. Westview Instruments, Inc., the U.S. Supreme Court held that in patent cases, the issue
of claim construction is a matter of law reserved for the district court judge, not the jury. 517 U.S. 370,
388–89 (1996). The Supreme Court recently reaffirmed this aspect of Markman. See Teva Pharm. v.
Sandoz, Inc., 135 S. Ct. 831, 835 (2015). Thus, judges now hold a pretrial claim construction hearing, or a
“Markman hearing,” to hear the parties’ arguments on how to construe the claims in the asserted patent.
Frank M. Gasparo, Markman v. Westview Instruments, Inc. and its Procedural Shock Wave: The Markman
Hearing, 5 J.L. & POL’Y 723, 724–25 (1997).
64
Trial judges, including those presiding over ANDA cases, are charged with the task of acting as
gatekeepers to expert testimony and must determine the reliability and relevance of an expert’s testimony
before it is admissible. See Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579, 597 (1993). Parties can
seek to exclude unreliable expert testimony by filing a pretrial motion known as a “Daubert motion.” See
Andrew Jurs, Gatekeeper with a Gavel: A Survey Evaluating Judicial Management of Challenges to Expert
Reliability and Their Relationship to Summary Judgment, 83 Miss. L.J. 325, 326 (2014).
65
See generally Chief J. Stark’s Patent Procedures, supra note 62.
66
Id. at 1 (emphasis in original).
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Order (non-ANDA) 67 and (2) Patent Scheduling Order (ANDA). 68 The non-ANDA patent
scheduling order contains a section for Chief Judge Stark to set a deadline for all case
dispositive motions, such as motions for summary judgment. 69 In comparison, his ANDA
patent scheduling order states: “[a]bsent agreement between the parties, the Court will
generally not hear case dispositive motions in ANDA cases.” 70
¶20
Unlike Chief Judge Stark, Judge Sue L. Robinson has only one patent case
scheduling order, which appears to apply to ANDA cases as well as non-ANDA. 71 Judge
Robinson’s patent scheduling order allows parties to file summary judgment motions with
no explicit constraint on parties to ANDA cases. 72 Judge Robinson also provides patent
litigants with certain guidelines that govern her courtroom; but again, she makes no
distinction between normal patent cases and ANDA cases. 73 For example, she permits
each party to file “one motion relating to infringement and one motion relating to
validity.” 74
¶21
Judge Gregory M. Sleet has implemented his own procedural rules to govern his
courtroom as well. Like Judge Robinson, he has only one scheduling order to govern all
patent cases. 75 However, his scheduling order requires that “[p]rior to filing any summary
judgment motion, the parties must submit letter briefs seeking permission to file the
motion.” 76 Also unique to Judge Sleet are his patent standing orders, which provide for
appointment of “special masters” to hear discovery disputes in patent cases. 77
67
Revised Patent Form Scheduling Order, U.S. DISTRICT CT. DISTRICT DEL. (June 2014),
http://www.ded.uscourts.gov/sites/default/files/Chambers/LPS/PatentProcs/LPS-PatentSchedOrder-NonANDA.pdf [https://perma.cc/65QV-DY7U] [hereinafter Chief J. Stark’s non-ANDA Patent Scheduling
Order].
68
Chief J. Stark’s ANDA Patent Scheduling Order, supra note 61.
69
See Chief J. Stark’s non-ANDA Patent Scheduling Order, supra note 67, at 11.
70
Chief J. Stark’s ANDA Patent Scheduling Order, supra note 61, at 10.
71
See J. Robinson’s Patent Scheduling Order, supra note 61.
72
See id.
73
See, e.g., Additional Civil Trial Guidelines for Patent Cases, U.S. DISTRICT CT. DISTRICT DEL. (Dec.
21, 2010),
http://www.ded.uscourts.gov/sites/default/files/Chambers/SLR/Misc/Additional_Civil_Trial_GuidelinesPatent_Cases_12-21-10.pdf [https://perma.cc/FA69-WR6W] [hereinafter J. Robinson’s Additional
Guidelines]; Briefing Guidelines in Complex Cases, U.S. DISTRICT CT. DISTRICT DEL. (Dec. 3, 2013),
http://www.ded.uscourts.gov/sites/default/files/Chambers/SLR/Misc/Briefing_Guidelines-Complex_Cases12-3-13.pdf [https://perma.cc/3QAG-G7HC] [hereinafter J. Robinson’s Briefing Guidelines]; Guidelines
for Claim Construction Rulings in Patent Cases, U.S. DISTRICT CT. DISTRICT DEL. (Dec. 21, 2010),
http://www.ded.uscourts.gov/sites/default/files/Chambers/SLR/Misc/Claim_Construction_Guideline_1221-10.pdf [https://perma.cc/Y9ZC-TZKE] [hereinafter J. Robinson’s Claim Construction Guidelines].
74
J. Robinson’s Briefing Guidelines, supra note 73, at 2.
75
Scheduling Order [Patent], U.S. DISTRICT CT. DISTRICT DEL. (Feb. 25, 2014),
http://www.ded.uscourts.gov/sites/default/files/Chambers/GMS/Forms/Sched_Order_Patent_Rev02-2514.pdf [https://perma.cc/C6RH-5Q79] [hereinafter J. Sleet’s Patent Scheduling Order].
76
Id. at 4 (emphasis added).
77
See, e.g., Special Master Standing Order, U.S. DISTRICT CT. DISTRICT DEL. (June 13, 2011),
http://www.ded.uscourts.gov/sites/default/files/Chambers/GMS/Orders/PDF/Special_Masters_Standing
Order_6-8-11.pdf [https://perma.cc/A8CR-LRZ2] [hereinafter J. Sleet’s Special Master Standing Order];
Procedures – Appointment of Special Masters to Hear Discovery Disputes in Intellectual Property Cases,
U.S. DISTRICT CT. DISTRICT DEL. (Sept. 2004),
http://www.ded.uscourts.gov/sites/default/files/Chambers/GMS/Orders/PDF/spmasproc.pdf
[https://perma.cc/T5CV-KWNY] [hereinafter J. Sleet’s Special Master Procedures]; Panel – Appoint of
Special Masters to Hear Discovery Disputes in Intellectual Property Cases, U.S. DISTRICT CT. DISTRICT
DEL. (Sept. 2004),
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Among Delaware’s four Article III judges, Judge Richard G. Andrews has the fewest
patent-specific procedures and guidelines. Like Judge Robinson and Judge Sleet, he has
only one scheduling order for patent cases. 78 Similarly, his patent scheduling order allows
parties to file case dispositive motions without reference to ANDA cases, 79 but his
scheduling order is the only explicit guideline applicable to patent cases in his courtroom. 80
What is unique about Judge Andrews’s scheduling order is that he has a unique procedure
for claim construction. 81 Instead of having the parties file separate claim construction
charts and briefs for the Markman hearing, he requires the parties to exchange their
proposed claim terms for construction, exchange their proposed constructions, confer, and
file a Joint Claim Construction Chart, as well as a Joint Claim Construction Brief. 82
III. EMPIRICAL STUDY: SUMMARY JUDGMENT PRACTICE IN DELAWARE VS.
NEW JERSEY

¶23

Along with the local rules, the local procedures for handling ANDA cases in the
District of Delaware and the District of New Jersey vary notably. Specifically, the two
districts differ significantly in how they handle summary judgment motions in ANDA
cases. This article presents an empirical study that compares the summary judgment
practice in the two districts. Like most litigation, the majority of ANDA cases end in
settlement. 83 Therefore, the number of final decisions on the merits to evaluate for this
study was limited. Nevertheless, the results of this empirical study show the general way
in which the two districts handle motions for summary judgment and the variance between
the districts’ practices. The data also reveals that the four Article III judges in Delaware
rarely allow parties to ANDA cases to bring motions for summary judgment.
A. Data Collection for the Empirical Study

¶24

This empirical study was conducted by collecting data from ANDA cases filed in the
Districts of Delaware and New Jersey between 2009 and 2013. The author searched the
dockets of the two districts for cases filed during the relevant time period using Bloomberg
Law’s docket search feature. The study was limited to ANDA cases filed on or after
January 1, 2009 through December 31, 2013. The dockets were searched using the
keywords “ANDA AND summary judgment” and “Hatch-Waxman AND summary
judgment.” The search found every case in those districts where a document on the docket

http://www.ded.uscourts.gov/sites/default/files/Chambers/GMS/Orders/PDF/spmaspanel.pdf
[https://perma.cc/4HAX-WBA7] [hereinafter J. Sleet’s Special Masters Panel].
78
See Scheduling Order, U.S. DISTRICT CT. DISTRICT DEL. (Apr. 2012),
http://www.ded.uscourts.gov/sites/default/files/Chambers/RGA/Forms/Rule16_Scheduling_OrderPatent.pdf [https://perma.cc/SSH5-L8TS] [hereinafter J. Andrews’s Patent Scheduling Order].
79
See id. at 6.
80
See Judge Richard G. Andrews, U.S. DISTRICT CT. DISTRICT DEL.,
http://www.ded.uscourts.gov/judge/judge-richard-g-andrews (last visited Mar. 10, 2016)
[https://perma.cc/DR7X-JJ9A].
81
See J. Andrew’s Patent Scheduling Order, supra note 78, at 3–4.
82
See id. at 3–5.
83
See 2014 Patent Litigation Study, supra note 33, at 21.
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contained the word “summary judgment” and either “ANDA” or “Hatch-Waxman” in its
title or body. 84
¶25
The author subsequently analyzed every docket sheet within those search parameters
and recorded whether a motion for summary judgment, request for leave to file a motion
for summary judgment, or both were filed within each case. 85 In analyzing those cases in
which a party filed a motion for summary judgment or sought leave to file a motion for
summary judgment, the author also recorded the judge’s decision.
B. The Results of the Study
¶26

The data collected from the empirical study is presented in Table I. Table I shows
the number of cases where a party brought at least one motion for summary judgment, the
number of cases where a motion was granted, and the number of cases where the judge
issued a summary judgment decision and that decision was case dispositive. Table I further
shows the number of cases where a party requested leave to file a motion for summary
judgment and whether that request was granted. Table I displays the data from the
empirical study by district. The data for the District of Delaware is further broken down
by judge since the procedures governing ANDA cases in Delaware vary by judge. 86 The
results for the District of New Jersey were not separated by judge because New Jersey has
six times the number of judges as the District of Delaware and has uniform patent rules
governing ANDA cases. Therefore, the author presumed that New Jersey was less likely
to have wide divergence between judges. The data presented in Table I was also organized
into Chart I to compare the summary judgment practice between the two districts. The data
for the District of Delaware was further arranged in Chart II to show the variance among
its four Article III judges.
TABLE I. SUMMARY JUDGMENT DATA FOR ANDA CASES 2009–2013 87
Delaware
New Jersey
Stark Robinson Sleet Andrews All Judges All Judges
Summary Judgment
Motions
2
1
0
4
7
31
Granted
Summary Judgment
Motions 88
1
1
0
2
4
10
84
The author acknowledges that the results are dependent upon the search terms used and Bloomberg
Law’s algorithm and is cognizant that there may be relevant cases that did not meet the search parameters.
However, the objective of the empirical study was to compare the general summary judgment practice in
the two districts in ANDA cases. Therefore, even if the data is not complete, the results are still useful for
showing this point.
85
If an ANDA case was filed before December 31, 2013 but the case had not reached the dispositive
motion stage, no data for that case was recorded.
86
See supra Section II(B).
87
For the data used to compile Table I, see Empirical Study Data, infra Appendix A.
88
If a motion for summary judgment was not granted, that does not necessarily mean that the
motion was denied. The results reflect only those cases where the judge reached a decision on the
summary judgment motion(s). There were two summary judgment motions filed in the District of
Delaware and recorded in Table I—one before Judge Andrews and the other before Judge Stark— that
were neither granted nor denied. See Medicis Pharm. Corp. v. Actavis Mid Atlantic LLC, No. 11-409 (D.
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Summary Judgment
Requests for Leave to
File a Motion for
Summary Judgment 89
Granted Requests for
Leave to File Motion
for Summary
Judgment 90
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0

1

0

2

3

1

2

0

4

4

10

1

0

0

0

1

1

1

CHART I. SUMMARY JUDGMENT DATA: DELAWARE & NEW JERSEY
35

Number of Cases

30
25
20
15
10
5
0

Summary
Judgment
Motions

Granted Cases Decided Requests for
Summary at Summary
Leave
Judgment
Judgment
Motions

Granted
Requests

Del. Apr. 12, 2013) (order granting parties’ joint stipulation of dismissal with prejudice); Novartis Pharm.
Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. July 7, 2013) (order granting the parties’ joint
stipulation of noninfringement and dismissing the case).
89

This data includes formal requests for leave as well as letters to judges requesting permission to
file a motion for summary judgment or to alter their usual practice of not allowing dispositive motions.
The author notes that there may have been informal requests that were not reflected on the dockets.
90
If a request for leave was not granted, that does not mean that the request was necessarily
denied. The results reflect only those cases where the judge reached a decision on the request. There was
one request for leave before Judge Andrews that was withdrawn before he rendered a decision. See
Novartis Pharm. Corp. v. Noven Pharm. Inc., No. 13-527 (D. Del. Oct. 22, 2014) (notice of withdrawal of
request for leave to file summary judgment).
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CHART II. SUMMARY JUDGMENT DATA IN DELAWARE BY JUDGE
5

Number of Cases

4

3

2

1

0

Summary
Judgment
Motions

¶27

Granted
Summary
Judgment
Motions

Cases Decided Requests for
at Summary
Leave
Judgment

Granted
Requests

Two things are apparent from the results of the empirical study: (1) the judges in the
District of Delaware rarely allow parties to bring motions for summary judgment, and (2)
there appears little uniformity among Delaware’s judges as to whether the motions will be
allowed.
C. Summary Judgment Is Rare in the District of Delaware

¶28

One thing is apparent from the results of the empirical study: the four judges in the
District of Delaware entertain few summary judgment motions in ANDA cases. From
2009–2013, litigants filed only seven motions for summary judgment before judges in the
District of Delaware. 91 This may be because litigants know Delaware judges rarely
entertain these motions or have realized that such motions are not successful in ANDA
cases in the district. Of those seven motions, four were granted 92 and three were case
91
Summary Judgment Data for ANDA Cases 2009–2013, supra Table I; see Motion for Summary
Judgment of Noninfringement by Upsher-Smith Labs. Inc., Auxilium Pharm. Inc. v. Upsher-Smith Labs.
Inc., No. 13-148 (D. Del. Apr. 5, 2013); Motion for Summary Judgment of Noninfringement by Alvogen
Grp. Inc., Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. June 24, 2014); Motion
for Summary Judgment of Invalidity by Mylan Institutional Inc., Spectrum Pharm. Inc. v. InnoPharma Inc.,
No. 12-260 (D. Del. Oct. 17, 2014); Motion for Partial Summary Judgment of Noninfringement by Actavis
Mid Atlantic LLC, Medicis Pharm. Corp. v. Actavis Mid Atlantic LLC, No. 11-409 (D. Del. Mar. 1, 2013);
Motion for Summary Judgment by Anchen Inc., Shire LLC v. Teva Pharm. USA Inc., No. 10-329 (D. Del.
June 20, 2012); Motion for Summary Judgment of Invalidity by Sandoz Inc., Wyeth Holdings Corp. v.
Sandoz Inc., No. 09-955 (D. Del. Feb. 10, 2012); Motion for Summary Judgment of Invalidity by Lupin
Ltd., Abbott Labs. v. Lupin Ltd., No. 09-152 (D. Del. Mar. 25, 2011).
92
Auxilium Pharm. Inc. v. Upsher-Smith Labs. Inc., No. 13-148 (D. Del. Dec. 4, 2013) (order granting
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dispositive. 93 In comparison, the District of New Jersey’s judges entertained thirty-one
motions and granted a third of those motions. 94 However, only one of those thirty-one
motions was case dispositive. 95 Since 2009, there have been 678 ANDA cases filed in the
District of Delaware and 481 filed in the District of New Jersey. 96 That means the District
of New Jersey handles thirty percent fewer ANDA cases than Delaware 97 but entertains
over four times the number of motions for summary judgment. 98 And while the District of
New Jersey entertains over four times the number of summary judgment motions, its judges
resolved fewer cases at summary judgment than Delaware’s judges between 2009 and
2013. 99
¶29
In the District of Delaware, parties sometimes seek leave to file a motion for
summary judgment. The requests, when made, are rarely granted. There were ten such
requests for leave filed between 2009 and 2013, 100 but only one of those requests was
motion for summary judgment of noninfringment); Spectrum Pharm. Inc. v. InnoPharma Inc., No. 12-260
(D. Del. Aug. 4, 2015) (order granting motions for summary judgment of noninfringement and invalidity);
Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. June 24, 2014) (order granting
defendants’ motion for summary judgment); Abbott Labs. v. Lupin Ltd., No. 09-152 (D. Del. May 19,
2011) (order denying defendants’ motion for summary judgment of invalidity and granting plaintiffs’
motion for summary judgment of validity).
93
Auxilium Pharm. Inc. v. Upsher-Smith Labs. Inc., No. 13-148 (D. Del. Dec. 30, 2013) (final judgment
of noninfringement); Spectrum Pharm. Inc. v. InnoPharma Inc., No. 12-260 (D. Del. Aug. 4, 2015) (order
directing clerk to close the case after holding the patents-in-suit invalid and not infringed); Novartis Pharm.
Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. July 7, 2014) (final judgment of noninfringement).
94
Summary Judgment Data for ANDA Cases 2009–2013, supra Table I; see Noven Pharm. v. Watson
Labs., Inc., No. 11-5997 (D.N.J. Nov. 26, 2013) (order granting defendants’ motion for summary judgment
of invalidity and noninfringement and denying plaintiff’s cross-motion for summary judgment of validity);
Shire LLC v. Amneal Pharm., LLC, No. 11-3781 (D.N.J. June 23, 2014) (order granting plaintiffs’ motions
for summary judgment in part and denying in part and granting defendants’ motions for summary judgment
in part and denying in part); Gilead Scis., Inc. v. Natco Pharm. Ltd., No. 11-1455 (D.N.J. Dec. 21, 2012)
(order granting plaintiffs’ motion for summary judgment); Braintree Labs., Inc. v. Novel Labs., Inc., No.
11-1341 (D.N.J. Jan. 18, 2013) (order granting plaintiff’s motions for summary judgment and denying
defendant’s motion for summary judgment); Prometheus Labs. Inc. v. Roxane Labs., Inc., No. 11-1241
(D.N.J. Dec. 16, 2013) (same); Prometheus Labs. Inc. v. Roxane Labs., Inc., No. 11-230 (D.N.J. Dec. 16,
2013) (same); Janssen Prods., L.P. v. Lupin Ltd., No. 10-5954 (D.N.J. Mar. 12, 2014) (order granting in
part and denying in part parties’ motions for summary judgment); Merck Sharp & Dohme Corp. v. Mylan
Pharm. Inc., No. 09-6383 (D.N.J. Aug. 22, 2011) (order granting in part and denying in part plaintiff’s
motions for summary judgment); Reckitt Benckiser Inc. v. Tris Pharma, Inc., No. 09-3125 (D.N.J. Dec. 21,
2011) (order granting defendant’s motion for summary judgment); Sunovion Pharm. Inc. v. Teva Pharm.
USA, Inc., No. 09-1302 (D.N.J. Jan. 1, 2013) (order granting defendants’ motion for summary judgment).
95
See Shire LLC v. Amneal Pharma., LLC, No. 11-3781 (D.N.J. July 21, 2014) (order of final
judgment).
96
Noonan, supra note 5.
97
See id.
98
See Summary Judgment Data for ANDA Cases 2009–2013, supra Table I.
99
See id.
100
See Letter from Defendants Requesting Summary Judgment Practice, Fresenius Kabi USA, LLC v.
Watson Labs. Inc., No. 13-1015 (D. Del. Mar. 4, 2014); Letter from Defendants Requesting Summary
Judgment Practice, Fresenius Kabi USA, LLC v. Dr. Reddy’s Labs. Ltd., No. 13-925 (D. Del. Mar. 4,
2014); Letter from Defendants Requesting Summary Judgment Practice, Novartis Pharm. Corp. v. Noven
Pharm. Inc., No. 13-527 (D. Del. Oct. 15, 2014); Motion for Leave to File a Summary Judgment Motion,
Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. May 29, 2014); Letter from
Defendants Requesting Leave to File a Summary Judgment Motion, Cubist Pharm., Inc. v. Hospira, Inc.,
No. 12-367 (D. Del. Oct. 8, 2013); Letter from Defendants Requesting Leave to File a Summary Judgment
Motion, Allergan Inc. v. Akorn Inc., No. 11-1270 (D. Del. May 24, 2012); Letter from Defendants
Requesting Leave to File a Summary Judgment Motion, Galderma Labs. Inc. v. Amneal Pharm. LLC, No.
11-1106 (D. Del. Apr. 17, 2012); Letter from Defendant Seeking Permission to File a Motion for Summary
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granted. 101 For example, Chief Judge Stark denied every request for leave during that time
period. 102 In fact, Judge Andrews was the only judge to grant a party’s request for leave. 103
In comparison, there was only one request for leave to file a motion for summary judgment
in New Jersey, and that request was granted. 104 This may be because the judges in New
Jersey regularly entertain motions for summary judgment in ANDA cases, and thus, parties
need not seek permission before filing.
D. Delaware’s Practice: Disjunctive or Consistent and Predictable?
¶30

The results from the empirical study show that the judges in the District of Delaware
do entertain motions for summary judgment occasionally, but the decision to hear such a
motion appears discretionary to each individual judge. 105 At first glance, the District of
Delaware’s practice may seem unpredictable and inconsistent. For example, Judge Sleet’s
patent scheduling order requires parties to seek permission before filing motions for
summary judgment, 106 but Judge Sleet denied every request between 2009 and 2013. 107 In
comparison, between 2009 and 2013, Chief Judge Stark did not grant a single request for
leave, yet he entertained motions for summary judgment in two cases where the parties did
not first request leave to file the motions. 108 Similarly, Judge Andrews granted only one
request for leave 109 but heard four motions for summary judgment. 110 On the other hand,
Judgment, AbbVie Inc. v. Hospira Inc., No. 11-648 (D. Del. Jan. 4, 2013); Letter from Defendants Seeking
Permission to File a Motion for Summary Judgment, Endo Pharm. Inc. v. Mylan Techs. Inc., No. 11-220
(D. Del. Apr. 15, 2013); Letter from Defendant Requesting Leave to File a Motion for Summary Judgment,
Roche Palo Alto LLC v. Endo Pharm. Inc., No. 10-261 (D. Del. June 4, 2010).
101
See Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. June 24, 2014) (order
granting defendants’ motion for leave to file a motion for summary judgment). Again, this study only
looked at formal requests for leave or requests made through letters written to the judge. Requests for leave
can also come through the scheduling order. See, e.g., AstraZeneca AV v. Aurobindo Pharma Ltd., No. 14664 (D. Del. Oct. 17, 2014) (consolidated) (granting a request for leave via the parties’ proposed
scheduling order). Requests for leave through the scheduling order were not looked at in this study, so
there may be additional requests and grants that were made via the Rule 16 conference and scheduling
order.
102
See Allergan Inc. v. Akorn Inc., No. 11-1270 (D. Del. June 21, 2012) (denying defendants’ request);
Galderma Labs. Inc. v. Amneal Pharm. LLC, No. 11-1106 (D. Del. Apr. 23, 2012) (same).
103
See Novartis Pharm., No. 13-52 (order granting defendants’ motion for leave).
104
See Sunovion Pharm. Inc. v. Teva Pharm. USA, Inc., No. 09-1302 (D.N.J. Oct. 1, 2011) (order
granting request for leave to file summary judgment motions).
105
See Summary Judgment Data for ANDA Cases 2009 – 2013, supra Table I.
106
See J. Sleet’s Patent Scheduling Order, supra note 75, at 4.
107
See Summary Judgment Data for ANDA Cases 2009 – 2013, supra Table I; Cubist Pharm., Inc. v.
Hospira, Inc., No. 12-367 (D. Del. Jan. 15, 2014) (order denying defendant’s letter request to file a motion
for summary judgment); AbbVie Inc. v. Hospira Inc., No. 11-648 (D. Del. Mar. 25, 2013) (oral order
denying letter request for permission to file a motion for summary judgment); Endo Pharm. Inc. v. Mylan
Techs. Inc., No. 11-220 (D. Del. May 3, 2013) (order denying letter request seeking leave to move for
summary judgment); Roche Palo Alto LLC v. Endo Pharm. Inc., No. 10-261 (D. Del. Feb. 23, 2011)
(stating that there will be no summary judgment practice during a telephone conference with the parties).
108
See Motion for Partial Summary Judgment of Noninfringement by Actavis Mid Atlantic LLC,
Medicis Pharm. Corp. v. Actavis Mid Atlantic LLC, No. 11-409 (D. Del. Mar. 1, 2013); Motion for
Summary Judgment of Invalidity by Lupin Ltd., Abbott Labs. v. Lupin Ltd., No. 09-152 (D. Del. Mar. 25,
2011). The author recognizes that the parties may have requested leave through the Rule 16 conference
and scheduling order, but no such request was present on the either case’s docket sheet.
109
See Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. June 24, 2014) (order
granting defendants’ motion for leave to file a motion for summary judgment).
110
See Motion for Summary Judgment of Noninfringement by Alvogen Grp. Inc., Novartis Pharm.
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in the only case where Judge Robinson granted a party’s request for leave, she also granted
that same party’s motion for summary judgment. 111 The results displayed in Chart II
further illustrate that the practices in the District of Delaware are “courtroom specific.” 112
¶31
The District of Delaware’s practice may seem inconsistent and discretionary, but
Delaware’s practice is actually quite uniform. While each judge has discretion over
whether he or she will entertain a motion for summary judgment or a request for leave to
file such a motion in an ANDA case, the four Article III judges are surprisingly consistent
in how they handle summary judgment motions. The results of the empirical study show
that, overall, the District of Delaware’s judges entertain very few requests for leave and
motions for summary judgment. 113 This practice is consistent across each of Delaware’s
four Article III judges. Therefore, the District of Delaware’s tendency to exclude summary
judgment practice in ANDA cases is actually consistent across the district. This gives
parties predictability.
IV. NO NEED FOR DELAWARE TO CHANGE ITS PROCEDURES IN ANDA CASES
¶32

Notwithstanding the variations among the judges’ standing orders, the investigation
into the District of Delaware’s practice and the empirical study highlights the remarkable
consistency between the judges in Delaware in granting—or even hearing—summary
judgment motions in ANDA cases. There are certainly differences in the judges’ standing
orders and summary judgment may not be an option for parties in ANDA cases in the
District of Delaware, but litigants know what to expect in each judge’s courtroom based
on their detailed standing orders and overall preference for no summary judgment motion
practice. The District of Delaware does not need to adopt uniform local patent rules or
specific Hatch-Waxman provisions as the District of New Jersey has done. Delaware could
be more receptive to summary judgment motions, but its current practice is efficient in
moving ANDA cases to trial, which are ultimately bench trials before the judge. However,
the District of Delaware could benefit by requiring early disclosure of the ANDA in these
cases.
A. The Purpose and Benefit of Local Patent Rules

¶33

Patent litigation imposes a number of additional “substantive, procedural, and
administrative challenges” on tribunals due to the highly technical and complex nature of
the subject matter. 114 Former Chief Judge Rader of the U.S. Court of Appeals for the
Federal Circuit acknowledged “that one of the greatest challenges in patent law is ‘the
Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. June 24, 2014); Motion for Summary Judgment of
Invalidity by Mylan Institutional Inc., Spectrum Pharm. Inc. v. InnoPharma Inc., No. 12-260 (D. Del. Oct.
17, 2014); Motion for Summary Judgment by Anchen Inc., Shire LLC v. Teva Pharm. USA Inc., No. 10329 (D. Del. June 20, 2012); Motion for Summary Judgment of Invalidity by Sandoz Inc., Wyeth Holdings
Corp. v. Sandoz Inc., No. 09-955 (D. Del. Feb. 10, 2012).
111
See Auxilium Pharm. Inc. v. Upsher-Smith Labs. Inc., No. 13-148 (D. Del. Dec. 4, 2013) (order
granting motion for summary judgment of noninfringment).
112
See Summary Judgment Data for ANDA Cases 2009 – 2013, supra Chart II.
113
See Summary Judgment Data for ANDA Cases 2009 – 2013, supra Table I.
114
Pauline M. Pelletier, The Impact of Local Patent Rules on Rate and Timing of Case Resolution
Relative to Claim Construction: An Empirical Study of the Past Decade, 8 J. BUS. & TECH. L. 451, 453
(2013).
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expense and delay of the litigation system.’” 115 However, the complex issues in patent
litigation can usually be narrowed to a short, critical list of case dispositive issues, such as
whether a patent claim is valid or whether the ANDA filer’s drug infringes the claim. 116
Thus, narrowing these issues early on in litigation reduces the complexity of the case. 117
¶34
Local patent rules can assist with narrowing complex patent infringement claims.
Such rules usually require patentees to serve and disclose to the alleged infringers their
asserted claims and infringement contentions. 118 These disclosures are typically in the
form of charts whereby the patentee compares its patent in detail — “claim-by-claim,
element-by-element” — with the alleged infringer(s)’s product(s). 119 Normal procedural
rules may be insufficient to handle complex patent litigation cases. For example, if a
patentee brings an infringement suit for its complicated patent containing fifty claims, the
defendant’s attorney—even if very knowledgeable in the specific art—“would have a
difficult time defending his client if the [patentee’s] attorney only made ‘a short and plain
statement of the claim showing that the pleader is entitled to relief.’” 120 Further, without
clear and organized contentions presented by the parties, it is difficult for a judge and
jury 121—who do not have a background in the technology—to understand the important
issues. 122
¶35
Along with reducing the complexity of patent cases, another major benefit of local
patent rules can be a quicker resolution of patent cases. 123 Patent rules can affect the timing
of a case, as well as the outcome. 124 Uniform rules can lead to fairly standard case
management within a district, relatively predictable case timelines, and overall “increased
efficiency.” 125
¶36
ANDA cases are unique from other forms of patent litigation. ANDA litigation
begins when a generic files a Paragraph IV certification in its ANDA arguing that the patent
is invalid, not infringed, or otherwise unenforceable. 126 The patent holder, usually a brandname drug company, can then bring suit against the generic after the generic files the
Paragraph IV certification because filing a Paragraph IV certification is a statutory-based

115

Id. at 462 (citations omitted).
See id.
117
Patent litigation issues do not become simple merely by narrowing the issues. The subject matter
remains highly technical, though there remain fewer case dispositive issues. For example, a pharmaceutical
patent may contain fifty claims, but judgment may turn on whether just one of those claims is valid. Thus,
by narrowing the issues in the case to whether that one claim is valid, the litigation becomes more focused.
118
Megan Woodhouse, Shop ‘Til You Drop: Implementing Federal Rules of Patent Litigation Procedure
to Wear Out Forum Shopping Patent Plaintiffs, 99 GEO. L.J. 227, 248 (2010).
119
See id. The patentee’s chart includes two columns. Id. The first column lists the asserted claim of
the patent and separates the claim’s elements by rows, “and the second column [compares] specific
information regarding the defendant’s product that allegedly infringes the elements of the [] patent.” Id.
Patentees must also provide “the details regarding the legal theories [they] are using to assert the claims in
the patent.” Id.
120
Id. 247–28 (quoting FED. R. CIV. P. 8(a)(2)).
121
While there are no juries in ANDA cases, there can be juries in other patent litigation suits. See
Coggio et al., supra note 42, at 767.
122
Woodhouse, supra note 118, at 248.
123
See Pelletier, supra note 114, at 463; Woodhouse, supra note 118, at 252–53.
124
See Jensen, supra note 47.
125
Pelletier, supra note 114, at 463. When case schedules are predictable, attorneys can better estimate
and stick to their clients’ case budgets. See Gollwitzer, supra note 47, at 94.
126
See 2014 Patent Litigation Study, supra note 33, at 20.
116
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act of infringement. 127 Frequently, the critical issue is whether the patent(s) on which the
generic seeks to market its generic equivalent is valid. 128 Additionally, because the HatchWaxman Act requires all Paragraph IV ANDA filers to provide notice to the challenged
patent holder, which “include[s] a detailed statement of the factual and legal basis” of why
the applicant believes “that the patent is invalid or will not be infringed,” the ANDA filer
is not in the same position as an accused infringer in a normal patent infringement action
before litigation commences. 129 Instead, the ANDA filer is well aware of the risks
associated with filing a Paragraph IV certification before it files the ANDA and has already
established its noninfringement or invalidity position before the patentee files suit. 130
1. Local Patent Rules Are Not Necessary in Delaware
¶37

It is no secret that the District of Delaware’s four Article III judges have extensive
patent experience and are some of the most experienced in the country in handling patent
infringement cases. 131 The District of Delaware leads all other district courts with the most
patent case filings per judge, which results in an experienced bench. 132 In fact, Judge
Andrews, Judge Robinson, Judge Sleet, and Chief Judge Stark are among the U.S. district
court judges who hear the most patent cases, 133 and they are the four judges that hear the
most ANDA cases in the country. 134 And when it comes to patent litigation, “[e]xperience
leads to efficiency, uniformity, and better case management.” 135 All four Article III judges
in the District of Delaware are extremely experienced and knowledgeable in patent issues
despite the district’s lack of uniform patent rules. Unlike judges who “lack[] prior patent
litigation experience [and] would benefit from patent trial rules,” 136 Delaware’s judges
have extensive experience and it may be superfluous for Delaware to adopt uniform local
patent rules.
¶38
The District of Delaware’s lack of local patent rules does not seem to have affected
the district’s case efficiency or time-to-trial. 137 Research “suggests that districts with local
127

See 35 U.S.C. § 271(e)(2)(A) (2015); 21 U.S.C. § 355(j)(5)(B)(iii) (2015).
See 2014 Patent Litigation Study, supra note 33, at 20.
129
21 U.S.C. § 355(j)(2)(B)(iv)(II).
130
See id.
131
See Comparison of the Most Popular Patent Venues, supra note 58.
132
See id. The most patent cases are filed in the Eastern District of Texas, and the District of Delaware
has the second most filings. Patent Litigation Statistics, IP LAW ALERT,
http://iplawalert.wp.lexblogs.com/wp-content/uploads/sites/242/2014/03/Patent-Litigation-Research.pdf
(last visited Mar. 13, 2016) [https://perma.cc/4S3D-6V8L]. These two districts “have nearly three times
the number of patent cases as the third busiest district, the Central District of California.” Charles H.
Chevalier et al., New Patent Case Scheduling Order Seeks to Achieve Efficiencies in Delaware, IP LAW
ALERT (Mar. 26, 2014), http://www.iplawalert.com/2014/03/articles/patent/new-patent-case-schedulingorder-seeks-to-achieve-efficiencies-in-delaware/ [https://perma.cc/KU4Z-XNGK]. However, the District
of Delaware has only four district court judges in comparison to eight in the Eastern District of Texas,
Judges, U.S. DISTRICT CT. E. DISTRICT TEX., http://www.txed.uscourts.gov/page1.shtml?location=info (last
visited Mar. 13, 2016) [https://perma.cc/99M3-HFND], and therefore has the most patent case filings per
judge.
133
See Patent Litigation Statistics, supra note 132; see also 2014 Patent Litigation Study, supra note 33,
at 22.
134
Noonan, supra note 5.
135
Woodhouse, supra note 118, at 252.
136
Id. at 247.
137
See 2013 Patent Litigation Study, supra note 45, at 30.
128
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patent rules process patent cases faster than districts lacking such rules.” 138 However, this
research is not dispositive. 139 Additionally, experienced judges can resolve cases more
quickly. 140 The District of Delaware has an overall faster time-to-trial—time from the day
the complaint is filed to the first day of trial—than the District of New Jersey for patent
cases that do not settle. 141 While local patent rules can decrease the time-to-trial,
Delaware’s experienced bench is efficient in resolving patent disputes.
¶39
Uniform local patent rules could still benefit Delaware’s experienced bench.
Although the District of Delaware’s judges are among the most knowledgeable in patent
issues, including ANDA cases, it may appear there is no uniformity among the judges.
Each judge has different standing orders that apply to cases in his or her courtroom, 142 and
the procedures governing ANDA cases in the District of Delaware are “courtroom specific”
and vary among the individual judges. 143 Uniform local patent rules can increase judicial
efficiency for inexperienced and experienced judges alike. 144 Local patent rules could only
improve the district’s efficiency in handling patent cases. However, because the District
of Delaware has only four Article III judges—all of whom are extremely knowledgeable
in patent issues—and patent litigation in that district is already more efficient than in other
districts that have adopted local patent rules, it is probably not necessary for the District of
Delaware to adopt local patent rules. 145
¶40
Even if the District of Delaware adopted local patent rules, thereby increasing
uniformity across its bench, that would not create uniformity among all patent litigation,
or more specifically, among ANDA litigation, in the United States. While many district
courts have adopted uniform local patent rules, those rules only apply to that specific
district. 146 Local patent rules vary widely among the twenty-four districts that have
formally adopted them. 147 This disunity can “yield legal clutter, undue complexity, and
unfairness” across patent litigation. 148

138
Gollwitzer, supra note 47, at 95 (discussing a study by LegalMetric that found “in districts adopting
local patent rules, the average time patent cases were pending decreased by 2 1/2 months when compared
to the average time pending prior to adopting the rules”).
139
See id. (noting that “[t]he two most notable patent ‘rocket-dockets,’ the Eastern District of Virginia
and the Western District of Wisconsin, have not adopted local patent rules”).
140
See Woodhouse, supra note 118, at 244 (“Experienced judges would be more familiar with the stages
of patent litigation, and trials would be faster.”).
141
See 2013 Patent Litigation Study, supra note 45, at 30. These statistics are not specific to ANDA
litigation but instead are general statistics of patent litigation in those districts. See id.
142
See Standing Orders, supra note 55.
143
See e.g., Chief J. Stark’s ANDA Patent Scheduling Order, supra note 61; J. Robinson’s Patent
Scheduling Order, supra note 61; J. Sleet’s Patent Scheduling Order, supra note 75; J. Andrews’s Patent
Scheduling Order, supra note 78.
144
See Woodhouse, supra note 118, at 252–53.
145
Adding local patent rules certainly would not hurt the district, but the district may not see much
benefit from adopting such rules. Local patent rules are designed to help judges inexperienced in patent
issues, see id., and that certainly is not the case on the District of Delaware’s bench.
146
See Pelletier, supra note 114, at 464.
147
See id.
148
Id.
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2. The Benefits of Early Disclosure in ANDA Cases
¶41

While the District of Delaware does not need local patent rules, it could consider
requiring generics to disclose the ANDA submitted to the FDA earlier in the litigation.
The Hatch-Waxman Act only requires that the ANDA filer give notice to the patentee when
it files a Paragraph IV certification in its ANDA. 149 This notice does not require the generic
to disclose the contents of its ANDA, but need only “include a detailed statement of the
factual and legal basis” of why the applicant believes “that the patent is invalid or will not
be infringed.” 150 Patent rules that require parties to make disclosures early on in the
litigation “enhances the transparency, organization, and accuracy of the patent litigation
process.” 151 This is especially true in ANDA cases where the generic has already submitted
a Paragraph IV certification to the FDA in its ANDA.
¶42
Prior to litigation, as required under the Hatch-Waxman Act, the ANDA filer has
already made certain contentions to the FDA in its Paragraph IV certification as to why the
patent is invalid or not infringed 152 and has provided notice to the patent holder of its factual
and legal theories behind its Paragraph IV certification. 153 The patent holder has forty-five
days to review the Paragraph IV certification before initiating an infringement suit. 154 This
puts the ANDA filer in a unique position before litigation commences and even before
filing its ANDA. By filing a Paragraph IV certification, the generic essentially asserts: (1)
that it has reviewed the patent(s), (2) that it believes the patent(s) is invalid or not infringed
by the generic’s drug, and (3) that it has researched the legal theories to support its position.
Requiring the ANDA filer to disclose the ANDA earlier in litigation, such as when it files
its answer, could increase transparency in the litigation since the ANDA filer is uniquely
situated and has already provided the FDA with substantially relevant information in its
ANDA, specifically, in its Paragraph IV certification.
¶43
The District of New Jersey has recognized this unique position ANDA litigants stand
in before litigation commences and has adopted unique early disclosure requirements that
apply specifically to ANDA cases. In 2010, New Jersey amended its local patent rules to
include specific disclosure provisions that govern all patents challenged by a Paragraph IV
certification in cases arising under the Hatch-Waxman Act. 155 The amendments impose
certain early disclosure requirements on both the party alleging patent infringement and
the ANDA filer. 156 Of particular importance is the amendment relating to early disclosure
of the ANDA. 157 The ANDA filer must produce the complete ANDA with its answer or
motion in response to the complaint, 158 disclose its noninfringement and invalidity
contentions for any patents referred to in its Paragraph IV certification within fourteen days

149

See 21 U.S.C. § 355(j)(2)(B)(iv)(II) (2015).
Id.
151
See Woodhouse, supra note 118, at 248.
152
See 21 U.S.C. § 355(j)(2)(A)(vii)(IV).
153
See id. § 355(j)(2)(B)(iv)(II).
154
See id. § 355(j)(5)(B)(iii).
155
See D.N.J. L. PAT. R. 3.6.
156
See id.
157
See id. 3.6(a).
158
See id. 3.6(a) (“On the date a party answers, moves, or otherwise responds, each party who is an
ANDA filer shall produce to each party asserting patent infringement the entire Abbreviated New Drug
Application or New Drug Application that is the basis of the case in question.”).
150
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after the initial Scheduling Conference, 159 produce all FDA communications pertaining to
the ANDA, and inform the FDA of any injunctions and motions in the case. 160
¶44
Due to the unique information the defendant in ANDA litigation acquires before
commencement of the suit, it is fair to require that party—the ANDA filer—to make these
early disclosures to the plaintiff. The ANDA filer has already made contentions in its
Paragraph IV certification and argued why the patent is invalid or not infringed, 161 and the
patentee has decided to refute those contentions. Like the District of New Jersey, the
District of Delaware should consider adopting similar early disclosure rules that require
the ANDA filer to (1) produce the complete ANDA with is answer or motion in response
to the complaint, (2) disclose its invalidity and non-infringement contentions first, and (3)
produce all FDA communications. 162
B. Is Summary Judgment Proper in ANDA Litigation?
¶45

Along with the District of Delaware’s predictable procedure governing ANDA cases,
the district’s summary judgment practice is efficient and consistent with the HatchWaxman’s purpose and policies. The District of Delaware rarely allows parties to bring a
summary judgment motion in ANDA cases. While the Federal Rules of Civil Procedure
explicitly permits parties to move for summary judgment, 163 there is usually a question of
fact in ANDA cases that should be decided at trial, not at summary judgment. 164
1. Summary Judgment Motions Are Not Necessary in ANDA Cases

¶46

Summary judgment motions are proper when “the movant shows that there is no
genuine dispute as to any material fact.” 165 Patent cases frequently involve a disagreement
over the facts, which is why “[i]t can be a significant waste of time and money to bring a

159
See id. 3.6(c) (“Not more than 14 days after the initial Scheduling Conference, each party opposing
an assertion of patent infringement shall provide to each party asserting patent infringement the written
basis for its ‘Invalidity Contentions,’ for all patents referred to in the opposing party’s Paragraph IV
Certification . . . .”); id. 3.6(e) (“Not more than 14 days after the initial Scheduling Conference, each party
opposing an assertion of patent infringement shall provide to each party asserting patent infringement the
written basis for its ‘Non-Infringement Contentions,’ for any patents referred to in the opposing party’s
Paragraph IV Certification which shall include a claim chart identifying each claim at issue in the case and
each limitation of each claim at issue.”).
160
See id. 3.6(j) (“Each party that has an ANDA application pending with the Food and Drug
Administration (“FDA”) that is the basis of the pending case shall: (1) notify the FDA of any and all
motions for injunctive relief no later than three business days after the date on which such a motion is filed;
and (2) provide a copy of all correspondence between itself and the FDA pertaining to the ANDA
application to each party asserting infringement . . . .”).
161
See 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (2015); see also Comparison of the Most Popular Patent
Venues, supra note 58 (recognizing that “[b]ecause of the triggers built into the [A]ct, . . . the potential
defendant knows the patents that will be asserted, the identity of the plaintiff, and the time frame for filing
the complaint”).
162
This would benefit the patentee because he would receive the ANDA filer’s ANDA and
noninfringement and invalidity contentions before having to narrow his claims asserted and infringement
contentions.
163
See FED. R. CIV. P. 56.
164
Sara Stefanini, Judges’ Top Four Pet Peeves in Patent Litigation, LAW360 (May 1, 2008),
http://www.law360.com/articles/54905/judges-top-four-pet-peeves-in-patent-litigation
[https://perma.cc/7XWF-FT2Q].
165
FED. R. CIV. P. 56(a).
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summary judgment motion.” 166 Former Judge Joseph J. Farnan of the District of Delaware
believes 90–95% of the time there is a dispute of facts, and thus summary judgment is
improper in ANDA cases. 167 Delaware’s Judge Sleet has stated that summary judgment
motions are unnecessary in ANDA cases, explaining that both parties usually “have experts
who are ready, willing and able to come to court and dispute the facts . . . .” 168 He has
asserted that in ANDA cases, a generic is usually attacking a patent for invalidly or
noninfringement, which almost always involves a dispute of facts. 169 Judge Sleet believes
ANDA cases are more effectively decided after hearing all the arguments, rather than at
summary judgment. 170 Since the resolution of many patent cases turns on a question of
fact, summary judgment may be unnecessary in most ANDA cases.
¶47
The data from the empirical study is illustrative of how few ANDA cases are resolved
at summary judgment. From 2009–2013, the District of New Jersey entertained thirty-one
motions for summary judgment and granted ten of those motions. 171 Two-thirds of those
motions were denied, and only one of those thirty-one motions was case dispositive. 172
That means that in the cases where a party moved for summary judgment in the District of
New Jersey, ninety-seven percent of those cases were not resolved at summary judgment
and continued towards trial. In comparison, the District of Delaware entertained two-thirds

166

Stefanini, supra note 164 (quoting Delaware’s former Chief Judge Sleet).
See id.
168
Id.
169
See id.
170
See id. Judge Sleet’s procedures reflect his viewpoint on summary judgment motions in ANDA
cases. For example, he requires parties to ask permission before filing a motion for summary judgment
“[t]o clamp down on filing that will undoubtedly lack merit in [ANDA] cases . . . .” Id.; see J. Sleet’s
Patent Scheduling Order, supra note 75. When a party seeks permission, Judge Sleet allows both parties to
argue their positions to him via teleconference. See Stefanini, supra note 164. However, he has started
taking the teleconferences off the case schedule and simply denying the requests generally because the facts
are usually disputed. See id.
171
See Summary Judgment Data for ANDA Cases 2009–2013, supra Table I; Noven Pharm. v. Watson
Labs., Inc., No. 11-5997 (D.N.J. Nov. 26, 2013) (order granting defendants’ motion for summary judgment
of invalidity and noninfringement and denying plaintiff’s cross-motion for summary judgment of validity);
Shire LLC v. Amneal Pharm., LLC, No. 11-3781 (D.N.J. June 23, 2014) (order granting plaintiffs’ motions
for summary judgment in part and denying in part and granting defendants’ motions for summary judgment
in part and denying in part); Gilead Scis., Inc. v. Natco Pharm. Ltd., No. 11-1455 (D.N.J. Dec. 21, 2012)
(order granting plaintiffs’ motion for summary judgment); Braintree Labs., Inc. v. Novel Labs., Inc., No.
11-1341 (D.N.J. Jan. 18, 2013) (order granting plaintiff’s motions for summary judgment and denying
defendant’s motion for summary judgment); Prometheus Labs. Inc. v. Roxane Labs., Inc., No. 11-1241
(D.N.J. Dec. 16, 2013) (same); Prometheus Labs. Inc. v. Roxane Labs., Inc., No. 11-230 (D.N.J. Dec. 16,
2013) (same); Janssen Prods., L.P. v. Lupin Ltd., No. 10-5954 (D.N.J. Mar. 12, 2014) (order granting in
part and denying in part parties’ motions for summary judgment); Merck Sharp & Dohme Corp. v. Mylan
Pharm. Inc., No. 09-6383 (D.N.J. Aug. 22, 2011) (order granting in part and denying in part plaintiff’s
motions for summary judgment); Reckitt Benckiser Inc. v. Tris Pharma, Inc., No. 09-3125 (D.N.J. Dec. 21,
2011) (order granting defendant’s motion for summary judgment); Sunovion Pharm. Inc. v. Teva Pharm.
USA, Inc., No. 09-1302 (D.N.J. Jan. 1, 2013) (order granting defendants’ motion for summary judgment).
172
See Shire LLC v. Amneal Pharma., LLC, No. 11-3781 (D.N.J. July 21, 2014) (order of final
judgment).
167
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fewer summary judgment motions than New Jersey 173 but resolved three times the number
of cases at summary judgment. 174
¶48
If a case ultimately involves a question of fact, the case proceeds more quickly to
trial by skipping the summary judgment stage. When a party or parties move for summary
judgment, there are usually lengthy motions and briefing by both parties on the issues. 175
This is burdensome on litigants and the court—in terms of resources, cost, and time—if
the case ultimately comes down to a question of fact that must be decided at trial. 176 In
other patent litigation disputes, parties may see summary judgment as the last opportunity
to have the judge decide and resolve the case before it goes to an unpredictable jury. 177
However, since ANDA cases are bench trials, the judge ultimately decides all issues at
trial. The risk of leaving those issues to an unpredictable jury if the case is not resolved at
summary judgment is not present in ANDA cases. If the judge is going to decide the case
anyway, then why not skip the lengthy summary judgment briefing and just have a trial?
¶49
The District of Delaware does not entertain many motions for summary judgment,
but that district does have an overall faster time-to-trial than the District of New Jersey in
patent litigation. 178 When Delaware’s four Article III judges skip the summary judgment
stage in ANDA cases altogether, the court does not waste time and resources on hearing
issues that the judge will ultimately need to decide at trial. Further, Delaware’s bench is
experienced and knowledgeable in patent issues, and specifically in ANDA issues, and
those judges are the ultimate decision makers at trial. 179 The District of Delaware’s
summary judgment practice in ANDA cases may be more efficient because then the judges

173

See Summary Judgment Data for ANDA Cases 2009–2013, supra Table I; Motion for Summary
Judgment of Noninfringement by Upsher-Smith Labs. Inc., Auxilium Pharm. Inc. v. Upsher-Smith Labs.
Inc., No. 13-148 (D. Del. Apr. 5, 2013); Motion for Summary Judgment of Noninfringement by Alvogen
Grp. Inc., Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. June 24, 2014); Motion
for Summary Judgment of Invalidity by Mylan Institutional Inc., Spectrum Pharm. Inc. v. InnoPharma Inc.,
No. 12-260 (D. Del. Oct. 17, 2014); Motion for Partial Summary Judgment of Noninfringement by Actavis
Mid Atlantic LLC, Medicis Pharm. Corp. v. Actavis Mid Atlantic LLC, No. 11-409 (D. Del. Mar. 1, 2013);
Motion for Summary Judgment by Anchen Inc., Shire LLC v. Teva Pharm. USA Inc., No. 10-329 (D. Del.
June 20, 2012); Motion for Summary Judgment of Invalidity by Sandoz Inc., Wyeth Holdings Corp. v.
Sandoz Inc., No. 09-955 (D. Del. Feb. 10, 2012); Motion for Summary Judgment of Invalidity by Lupin
Ltd., Abbott Labs. v. Lupin Ltd., No. 09-152 (D. Del. Mar. 25, 2011).
174
See Auxilium Pharm. Inc. v. Upsher-Smith Labs. Inc., No. 13-148 (D. Del. Dec. 30, 2013) (final
judgment of noninfringement); Spectrum Pharm. Inc. v. InnoPharma Inc., No. 12-260 (D. Del. Aug. 4,
2015) (order directing clerk to close the case after holding the patents-in-suit invalid and not infringed);
Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. July 7, 2014) (final judgment of
noninfringement).
175
See D. Theodore Rave, Questioning the Efficiency of Summary Judgment, 81 N.Y.U. L. REV. 875,
894 (2006) (discussing how “the parties have an incentive to engage the merits of the case with full briefing
and presentation of evidence—in essence, a dress rehearsal of the trial”).
176
See id. at 876 (“Modern summary judgment, however, is a frequently used motion that is costly to
oppose and, if not granted often enough, may be a net drain on society.”)
177
See Jennifer F. Miller, Should Juries Hear Complex Patent Cases?, 4 DUKE L. & TECH. REV. 1, 32
(2004) (discussing the concerns that decisions by juries in complex patent cases “are arbitrary,
unpredictable, and based on considerations other than the relevant law”); but see Michael J. Mazzeo et al.,
Explaining the “Unpredictable”: An Empirical Analysis of U.S. Patent Infringement Awards, 35 INT’L
REV. L. & ECON. 58, 69 (presenting an empirical study showing the fear and concern of unpredictable
patent infringement awards by juries may be unfounded).
178
See 2013 Patent Litigation Study, supra note 45, at 30.
179
See Comparison of the Most Popular Patent Venues, supra note 58; see also Patent Litigation
Statistics, supra note 132; Chevalier et al., supra note 132.
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do not waste time hearing and ruling on ultimately pointless summary judgment motions
that they will ultimately have to decide at trial.
¶50
However, summary judgment can be practical in some ANDA cases. While HatchWaxman cases commonly involve questions of fact, there are situations in which there is
no dispute of fact. Of the seven motions for summary judgment filed between 2009 and
2013 in the District of Delaware, over half of those motions were granted. 180 Those
motions could not have been granted if there was a “genuine dispute as to any material
fact.” 181
2. Delaware’s Practice Is Consistent with the Purpose of the Hatch-Waxman Act
¶51

The District of Delaware’s practice does not undermine the goal of the HatchWaxman Act: to get non-infringing, low-cost generic equivalents on the market faster. 182
Commencement of ANDA litigation halts the FDA’s approval process until resolution of
the case, and this stay can last up to thirty months. 183 With little to no chance of being able
to bring a summary judgment motion and dispose of the case before trial, it may seem like
the District of Delaware’s practice is contrary to the purpose of the Hatch-Waxman Act.
However, bypassing the summary judgment stage for ANDA cases may increase case
efficiency and quicken the time-to-trial if most ANDA cases ultimately come down to a
question of fact. When ANDA litigation is resolved more quickly, the generic drugs
subject to litigation are put in the hands of American consumers more quickly.
CONCLUSION

¶52

ANDA litigation is on the rise. The number of ANDA cases filed increases each
year, 184 and “the number of court decisions from ANDA litigation has grown substantially
. . . .” 185 Since the District of Delaware hears the most ANDA cases of any district court,
its local rules and summary judgment practice affects a substantial amount of ANDA
litigation. Thus, the District of Delaware’s procedures can affect more than just the ANDA
parties before the court; it can have a dramatic effect on the entire pharmaceutical industry.

180

See Auxilium Pharm. Inc. v. Upsher-Smith Labs. Inc., No. 13-148 (D. Del. Dec. 4, 2013) (order
granting motion for summary judgment of noninfringment); Spectrum Pharm. Inc. v. InnoPharma Inc., No.
12-260 (D. Del. Aug. 4, 2015) (order granting motions for summary judgment of noninfringement and
invalidity); Novartis Pharm. Corp. v. Alvogen Pine Brook Inc., No. 13-52 (D. Del. June 24, 2014) (order
granting defendants’ motion for summary judgment); Abbott Labs. v. Lupin Ltd., No. 09-152 (D. Del. May
19, 2011) (order denying defendants’ motion for summary judgment of invalidity and granting plaintiffs’
motion for summary judgment of validity).
181
See FED. R. CIV. P. 56(a).
182
See H.R. REP. NO. 98–857, pt. 1, at 14 (1984) (“The purpose of Title I of the bill is to make available
more low cost generic drugs by establishing a generic drug approval procedure for pioneer drugs first
approved after 1962.”); Avery, supra note 8, at 172.
183
See 21 U.S.C. § 355(j)(5)(B)(iii) (2015).
184
See Howard, supra note 5, at 13 (noting that “ANDA case filings have risen slightly in 2014”). This
trend is “consistent with the upward trend of overall patent litigation . . . .” 2014 Patent Litigation Study,
supra note 33, at 20.
185
2014 Patent Litigation Study, supra note 33, at 20. Courts handed down an average of eighteen
ANDA decisions per year from 2010 to 2013 as compared to only eight decisions per year from 2005 to
2009. Id. That is a 225% increase in decisions in just four years! See id.
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The district’s procedures and summary judgment practice does not delay consumer access
to affordable generic drugs.
¶53
The District of Delaware does not need to adopt local patent rules because its four
Article III judges are already knowledgeable and efficient in handling ANDA cases. While
procedures governing ANDA cases vary between Delaware’s four Article III judges, once
a litigant knows which judge his or her case is before, the case schedule is predictable.
However, due to the unique information the defendant in ANDA litigation acquires before
litigation commences, the District of Delaware could consider adopting early disclosure
provisions that require that party—the ANDA filer—to (1) produce the complete ANDA
with is answer or motion in response to the complaint, (2) disclose its invalidity and
noninfringement contentions first, and (3) produce all FDA communications.
¶54
The District of Delaware should continue with its practice of only hearing summary
judgment motions in the exceptional case because most ANDA cases involve questions of
fact. If a party brings a summary judgment motion, it can be a waste of court resources
and time when the motion is eventually denied and the case progresses towards trial. By
skipping summary judgment, ANDA cases proceed more quickly to trial where ultimately
a judge, and not a jury, will decide the issues. The District of Delaware’s judges are
efficient in handling and resolving ANDA cases, so this practice does not keep those lowcost alternatives off the shelf and out of reach of American consumers.
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APPENDIX A: Empirical Study Data
Table II. Delaware Cases Used in the Empirical Study
Parties
Fresenius Kabi USA LLC v. Watson Labs. Inc.
Fresenius Kabi USA LLC v. Dr. Reddy’s Labs. Ltd.
Novartis Pharm. Corp. v. Noven Pharm. Inc.
Auxilium Pharm. Inc. v. Upsher-Smith Labs. Inc.
Novartis Pharm. Corp. v. Alvogen Pine Brook Inc.
Cubist Pharm. Inc. v. Hospira Inc.
Spectrum Pharm. Inc. v. InnoPharma Inc.
Allergan Inc. v. Akorn Inc.
Galderma Labs. Inc. v. Amneal Pharm. LLC
AbbVie Inc. v. Hospira Inc.
Medicis Pharm. Corp. v. Actavis Mid Atlantic LLC
Abbott Prods. Inc. v. Teva Pharm. USA Inc.
Endo Pharm. Inc. v. Mylan Tech. Inc.
Shire LLC v. Teva Pharm. USA Inc.
Wyeth Holdings Corp. v. Sandoz Inc.
Roche Palo Alto LLC v. Endo Pharm. Inc.
Abbott Labs. v. Lupin Ltd.

Docket Number
No. 13-1015
No. 13-925
No. 13-527
No. 13-148
No. 13-52
No. 12-367
No. 12-260
No. 11-1270
No. 11-1106
No. 11-648
No. 11-409
No. 11-384
No. 11-220
No. 10-329
No. 09-955
No. 10-261
No. 09-152

Date Filed
June 6, 2013
May 23, 2013
Apr. 3, 2013
Jan. 28, 2013
Jan. 4, 2013
Mar. 21, 2012
Mar. 2, 2012
Dec. 21, 2011
Nov. 8, 2011
July 21, 2011
May 11, 2011
Apr. 29, 2011
Mar. 14, 2011
Apr. 22, 2010
Dec. 11, 2009
Mar. 31, 2009
Mar. 6, 2009

Table III. New Jersey Cases Used in the Empirical Study
Parties
United Therapeutics Corp. v. Sandoz, Inc.
AstraZeneca AB v. Dr. Reddy’s Labs., Inc.
Auxilium Pharm., Inc. v. Watson Labs., Inc.
Warner Chilcott Co. v. Amneal Pharm., LLC
United Therapeutics Corp. v. Sandoz, Inc.
Shire LLC v. Watson Labs. Inc.
Santarus, Inc. v. Zydus Pharm. (USA) Inc.
MSD Consumer Prods., Inc. v. Zydus Pharm. (USA) Inc.
Noven Pharm. v. Watson Labs., Inc.
Helsinn Healthcare S.A. v. Dr. Reddy’s Labs., Ltd.
Shire LLC v. Amneal Pharm., LLC
Hoffmann-La Roche Inc. v. Teva Pharm. USA, Inc.
The Medicines Co. v. Dr. Reddy’s Labs. Ltd.
AstraZeneca AB v. Dr. Reddy’s Labs. Inc.
Gilead Scis., Inc. v. Natco Pharma Ltd.
Braintree Labs., Inc. v. Novel Labs., Inc.
Prometheus Labs. Inc. v. Roxane Labs., Inc.
Prometheus Labs. Inc. v. Roxane Labs., Inc.
Janssen Prods., L.P. v. Lupin Ltd.
Abbott Labs. v. Lupin Ltd.
Teva Women’s Health, Inc. v. Mylan Pharm., Inc.

Docket Number
No. 13-316
No. 13-91
No. 12-3084
No. 12-2928
No. 12-1617
No. 12-83
No. 11-7441
No. 11-7437
No. 11-5997
No. 11-3962
No. 11-3781
No. 11-3635
No. 11-2456
No. 11-2317
No. 11-1455
No. 11-1341
No. 11-1241
No. 11-230
No. 10-5954
No. 10-1578
No. 10-1234

Date Filed
Jan. 16, 2013
Jan. 4, 2014
May 23, 2012
May 16, 2012
Mar. 14, 2012
Jan. 5, 2012
Dec. 21, 2011
Dec. 21, 2011
Oct. 13, 2011
July 8, 2011
June 30, 2011
June 23, 2011
Apr. 28, 2011
Apr. 21, 2011
Mar. 15, 2011
Mar. 9, 2011
Mar. 4, 2011
Jan. 14, 2011
Nov. 15, 2010
Mar. 26, 2010
Mar. 9, 2010
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Graceway Pharm., LLC v. Perrigo Co.
Teva Women’s Health, Inc. v. Lupin, Ltd.
Merck Sharp & Dohme Corp. v. Mylan Pharm. Inc.
Merck Sharp & Dohme Corp. v. Apotex Inc.
Hospira, Inc. v. Sandoz Int’l GmbH
Reckitt Benckiser Inc. v. Tris Pharma, Inc.
Hoffmann-La Roche Inc. v. Mylan Inc.
Sunovion Pharm. Inc. v. Teva Pharm. USA, Inc.
Merck & Co., Inc. v. Sandoz Inc.
Dr. Reddy’s Labs., Ltd. v. Eli Lilly & Co.

Katherine Rhoades

No. 10-937
No. 10-80
No. 09-6383
No. 09-6373
No. 09-4591
No. 09-3125
No. 09-1692
No. 09-1302
No. 09-890
No. 09-192

Feb. 23, 2010
Jan. 6, 2010
Dec. 16, 2009
Dec. 18, 2009
Sept. 4, 2009
June 26, 2009
Apr. 8, 2009
May 20, 2009
Feb. 27, 2009
Jan. 8, 2009
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